- Stocks
- Healthcare
- NASDAQ: HZNP

Price (delayed)

$78.72

Market cap

$17.37B

P/E Ratio

19.06

Dividend/share

N/A

EPS

$4.13

Enterprise value

$16.65B

Sector: Healthcare

Industry: Drug Manufacturers - General

The equity has soared by 144% year-on-year and by 61% since the previous quarter

Horizon Therapeutics's quick ratio has surged by 141% QoQ and by 54% YoY

The stock's price to earnings (P/E) is 29% more than its last 4 quarters average of 14.8

What are the main financial stats of HZNP

Market
Valuations
Earnings

Shares outstanding

220.71M

Market cap

$17.37B

Enterprise value

$16.65B

Price to earnings (P/E)

19.06

Price to book (P/B)

4.28

Price to sales (P/S)

9.19

EV/EBIT

60.72

EV/EBITDA

30.61

EV/Sales

9.15

Revenue

$1.82B

EBIT

$274.18M

EBITDA

$543.91M

Free cash flow

$197.32M

Per share
Balance sheet
Liquidity

EPS

$4.13

Free cash flow per share

$0.93

Book value per share

$18.39

Revenue per share

$8.57

TBVPS

$16.51

Total assets

$5.77B

Total liabilities

$1.97B

Debt

$1B

Equity

$3.8B

Working capital

$1.95B

Debt to equity

0.26

Current ratio

3.49

Quick ratio

3.11

Net debt/EBITDA

-1.34

Margins
Efficiency
Dividend

EBITDA margin

29.9%

Gross margin

74.4%

Net margin

43.5%

Operating margin

16.8%

Return on assets

16.6%

Return on equity

30.1%

Return on invested capital

14.2%

Return on capital employed

5.5%

Return on sales

15.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Horizon Therapeutics stock price performed over time

Intraday

-0.24%

1 week

-1.03%

1 month

2.1%

1 year

108.59%

YTD

7.61%

QTD

7.61%

How have Horizon Therapeutics's revenue and profit performed over time

Revenue

$1.82B

Gross profit

$1.35B

Operating income

$305.67M

Net income

$792.01M

Gross margin

74.4%

Net margin

43.5%

The operating income has surged by 143% since the previous quarter and by 98% year-on-year

The company's operating margin has surged by 102% QoQ and by 41% YoY

HZNP's net income has surged by 53% since the previous quarter

HZNP's gross profit is up by 46% year-on-year and by 21% since the previous quarter

What is Horizon Therapeutics's growth rate over time

What is Horizon Therapeutics stock price valuation

P/E

19.06

P/B

4.28

P/S

9.19

EV/EBIT

60.72

EV/EBITDA

30.61

EV/Sales

9.15

Horizon Therapeutics's EPS has increased by 45% from the previous quarter

The stock's price to earnings (P/E) is 29% more than its last 4 quarters average of 14.8

The equity has soared by 144% year-on-year and by 61% since the previous quarter

HZNP's price to book (P/B) is 53% higher than its 5-year quarterly average of 2.8 and 19% higher than its last 4 quarters average of 3.6

HZNP's price to sales (P/S) is 163% more than its 5-year quarterly average of 3.5 and 46% more than its last 4 quarters average of 6.3

Horizon Therapeutics's revenue has increased by 41% YoY and by 20% from the previous quarter

How efficient is Horizon Therapeutics business performance

HZNP's return on invested capital has surged by 118% year-on-year

Horizon Therapeutics's ROS has soared by 104% YoY

Horizon Therapeutics's return on assets has increased by 36% QoQ

HZNP's ROE is up by 20% from the previous quarter

What is HZNP's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for HZNP.

How did Horizon Therapeutics financials performed over time

The total assets is 193% more than the total liabilities

Horizon Therapeutics's quick ratio has surged by 141% QoQ and by 54% YoY

Horizon Therapeutics's current ratio has surged by 131% QoQ and by 50% YoY

The company's debt is 74% lower than its equity

The equity has soared by 144% year-on-year and by 61% since the previous quarter

The debt to equity has dropped by 70% year-on-year and by 48% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.